TTrialPathMatch Me to Trials
← Back to trials
RecruitingCentral Line Associated Blood Stream Infections (CLABSI)

Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)

Eligible age

12+ yrs

Accepts

All genders

Locations

16 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a Phase 3, randomized, double-blind, controlled, adaptive, 2-arm, multicenter study to demonstrate the efficacy and safety of DefenCath in adult and adolescent participants receiving home Total Parenteral Nutrition (TPN) via Central Venous Catheter (CVC) compared with heparin.

Sponsor: CorMedix Therapeutics

You may not qualify if…

  • ✕ 1. Any participant unable or not willing to sign inform consent or, in the case of adolescents, not willing to provide assent.
  • ✕ 2. Any participant who is currently receiving systemic antibiotics. Topical antibiotics are permitted. Use of metronidazole or rifaximin for treating small intestinal bacterial overgrowth (SIBO) is also permitted.
  • ✕ 3. Any participant with visible evidence of compromised skin integrity present at the catheter exist site or catheter exit site infection.
  • ✕ 4. Any participant with a secondary CVC in addition to the primary TPN line.
  • ✕ 5. Any participant that has received thrombolytic treatment (e.g., tissue-type plasminogen activator \[tPA\]-Cathflo), not as a part of the institution's standard of care for patency management, in current catheter within 30 days of randomization.
  • ✕ 6. Any participant with unstable arrhythmia, defined as presence of hemodynamic instability within a month prior to the baseline assessment.
  • ✕ 7. Any participant using any type of antimicrobial-coated or heparin-coated catheter.
  • ✕ 8. Any participant with documented chronic bleeding diathesis, active or recurrent bleeding within 1 month prior to randomization.

Where it's recruiting

California

Los Angeles

District of Columbia

Washington D.C.

Florida

Doral

Georgia

Atlanta

Illinois

Chicago · Maywood

Iowa

Iowa City

Maryland

Baltimore

Minnesota

Rochester

New York

New York

Ohio

Cleveland

Source: ClinicalTrials.gov · NCT06822426 · last updated 2026-09-25